Overview of gp96 mediated immunity

Shengwu Gongcheng Xuebao/Chinese Journal of Biotechnology

Volumn 27, Issue 5, 2011, Pages 704-711

  Chen, Caiwei ^a   Jia, Xiaojuan ^a   Meng, Songdong ^a   Liu, Wenjun ^a  

^a INSTITUTE OF MICROBIOLOGY   (China)

Author keywords

Adjuvant; Antigen cross presentation; Gp96; Heat shock protein

Indexed keywords

ENDOPLASMIN; IMMUNOLOGICAL ADJUVANT; MEMBRANE PROTEIN;

ANTIGEN PRESENTING CELL; ARTICLE; COMMUNICABLE DISEASE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; ENDOPLASMIC RETICULUM; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; NEOPLASM; PHYSIOLOGY;

ADJUVANTS, IMMUNOLOGIC; ANTIGEN-PRESENTING CELLS; COMMUNICABLE DISEASES; DENDRITIC CELLS; ENDOPLASMIC RETICULUM; HUMANS; MEMBRANE GLYCOPROTEINS; NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 79961004870     PISSN: 10003061     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Lindquist S, Craig E A. The heat-shock proteins. Annu Rev Genet, 1988, 22: 631-677.
2. Hartl F U. Molecular chaperones in cellular protein folding. Nature, 1996, 381(6583): 571-579.
3. Berwin B, Rosser M F, Brinker K G, et al. Transfer of GRP94 (Gp96)-associated peptides onto endosomal MHC class I molecules. Traffic, 2002, 3(5): 358-366.
4. Bolhassani A, Rafati S. Heat-shock proteins as powerful weapons in vaccine development. Expert Rev Vaccines, 2008, 7(8): 1185-1199.
5. Linderoth N A, Popowicz A, Sastry S. Identification of the peptide-binding site in the heat shock chaperone/tumor rejection antigen Gp96 (Grp94). J Biol Chem, 2000, 275(8): 5472-5477.
6. Dollins D E, Warren J J, Immormino R M, et al. Structures of GRP94-nucleotide complexes reveal mechanistic differences between the hsp90 chaperones. Mol Cell, 2007, 28(1): 41-56.
7. Thorne M E, McQuade K L. Heat-induced oligomerization of gp96 occurs via a site distinct from substrate binding and is regulated by ATP. Biochem Biophys Res Commun, 2004, 323(4): 1163-1171.
8. Ding F X, Wang F, Lu Y M, et al. Multiepitope peptide-loaded virus-like particles as a vaccine against hepatitis B virus-related hepatocellular carcinoma. Hepatology, 2009, 49(5): 1492-1502.
9. Li Y, Song H, Li J, et al. Hansenula polymorpha expressed heat shock protein gp96 exerts potent T cell activation activity as an adjuvant. J Biotechnol, 2011, 151(4): 343-349.
10. Arnold-Schild D, Hanau D, Spehner D, et al. Receptor-mediated endocytosis of heat shock proteins by professional antigen-presenting cells. J Immunol, 1999, 162: 3757-3760.
11. di Pietro A, Tosti G, Ferrucci P F, et al. Heat shock protein peptide complex 96-based vaccines in melanoma: how far we are, how far we can get. Hum Vaccin, 2009, 5(11): 727-737.
12. Beg A A. Endogenous ligands of Toll-like receptors: implications for regulating inflammatory and immune responses. Trends Immunol, 2002, 23(11): 509-512.
13. Dai J, Liu B, Caudill M M, et al. Cell surface expression of heat shock protein gp96 enhances cross-presentation of cellular antigens and the generation of tumor-specific T cell memory. Cancer Immunol, 2003, 3: 1-11.
14. Chandawarkar R Y, Wagh M S, Srivastava P K. The dual nature of specific immunological activity of tumor-derived gp96 preparations. J Exp Med, 1999, 189(9): 1437-1442.
15. Suto R, Srivastava P K. A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides. Science, 1995, 269(5230): 1585-1588.
16. Zheng H, Dai J, Stoilova D, et al. Cell surface targeting of heat shock protein gp96 induces dendritic cell maturation and antitumor immunity. J Immunol, 2001, 167(12): 6731-6735.
17. Radsak M P, Hilf N, Singh-Jasuja H, et al. The heat shock protein gp96 binds to human neutrophils and monocytes and stimulates effector functions. Blood, 2003, 101(7): 2810-2815.
18. Basu S, Binder R J, Suto R, et al. Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-kappa B pathway. Int Immnol, 2000, 12(11): 1539-1546.
19. Banerjee P P, Vinay D S, Mathew A, et al. Evidence that glycoprotein 96(B2), a stress protein, functions as a Th2-specific costimulatory molecule. J Immunol, 2002, 169(7): 3507-3518.
20. Srivastava P K, Udono H, Blachere N E, et al. Heat shock proteins transfer peptides during antigen processing and CTL priming. Imunogenetics, 1994, 39(2): 93-98.
21. Wills A D, Malkovasky M. Heat shock proteins, tumor immunogenicity and antigen presentation: an integrated view. Immunol Today, 2000, 21(3): 129-132.
22. Singh-Jasuja H, Scherer H U, Hilf N, et al. The heat shock protein gp96 induces maturation of dendritic cells and down-regulation of its receptor. Eur J Immunol, 2000, 30(8): 2211-2215.
23. Liu B, Dai J, Zheng H, et al. Cell surface expression of an endoplasmic reticulum resident heat shock protein gp96 triggers MyD88-dependent systemic autoimmune diseases. Proc Natl Acad Sci USA, 2003, 100(26): 15824-15829.
24. Zügel U, Sponaas A M, Neckermann J, et al. Gp96-peptide vaccination of mice against intracellular bacteria. Infect Immunol, 2001, 69(6), 4164-4167.
25. Blachere N E, Li Z, Chandawarkar R Y, et al. Heat shock protein-peptide complexes, reconstituted in vitro, elicit peptide-specific cytoxic T lymphocyte response and tumor immunity. J Exp Med, 1997, 186(8): 1315-1322.
26. Blachere N E. The role of heat shock proteins in antigen presentation by MHC class I molecules[D]. Bronx: Fordam University, 1998.
27. Heikema A, Agsteribbe E, Wischut J, et al. Generation of heat shock protein-based vaccines by intracellular loading of gp96 with antigenic peptides. Immunol Lett, 1997, 57(1/3): 69-74.
28. Li H, Zhou M, Han J, et al. Generation of murine CTL by a hepatitis B virus-specific peptide and evaluation of the adjuvant effect of heat shock protein glycoprotein 96 and its terminal fragments. J Immunol, 2005, 174(1): 195-204.
29. Li H T, Yan J B, Li J, et al. Enhancement of humoral immune responses to HBsAg by heat shock protein gp96 and its N-terminal fragment in mice. World J Gastroenterol, 2005, 11(19): 2858-2863.
30. Li Z, Dai J, Zheng H, et al. An integrated view of the roles and mechanisms of heat shock protein gp96-peptide complex in eliciting immune response. Front Biosci, 2002, 7: d731-d751.
31. Liu Z, Li X H, Qiu L P, et al. Treg suppress CTL responses upon immunization with HSP gp96. Eur J Immunol, 2009, 39(11): 3110-31120.
32. Gong X Y, Gai W W, Xu J Q, et al. Glycoprotein 96-mediated presentation of human immunodeficiency virus type 1 (HIV-1)-specific human leukocyte antigen class I-restricted peptide and humoral immune responses to HIV-1 p24. Clin Vaccine Immunol, 2009, 16(11): 1595-1600.
33. Pakravan N, Hashemi S M, Hassan Z M. Adjuvant activity of GP96 C-terminal domain towards Her2/neu DNA vaccine is fusion direction-dependent. Cell Stress Chaperones, 2010, 16(1): 41-48.
34. Pakravan P, Soleimanjahi H, Hassan Z M. GP96 C-terminal improves Her2/neu DNA vaccine. J Gene Med, 2010, 12(4): 345-353.
35. Tamura Y, Peng P, Liu K, et al. Immunotherapy of tumors with antologous tumor-derived heat shock protein preparations. Science, 1997, 278(5335): 117-120.
36. Janetzki S, Blachere N E, Srivastava P K. Generation of tumor-specific cytotoxic T lymphocytes and memory T cells by immunization with tumor-derived heat shock protein gp96. J Immunother, 1998, 21(4): 269-276.
37. Lau R, Wang F, Jeffery G, et al. Phase I trial of intravenous peptide-pulsed dendritic cells in patients with metastatic melanoma. J Immunother, 2001, 24(1): 66-78.
38. Belli F, Testori A, Rivoltini L, et al. Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. J Clin Oncol, 2002, 20(20): 4169-4180.
39. Tosti G, di Pietro A, Ferrucci P F, et al. HSPPC-96 vaccine in metastatic melanoma patients: from the state of the art to a possible future. Expert Rev Vaccines, 2009, 8(11): 1513-1526.
40. Ménoret A, Chandawarkar R Y, Srivastava P K. Natural autoantibodies against heat-shock proteins hsp70 and gp96: implications for immunotherapy using heat-shock proteins. Immunology, 2000, 101(3): 364-370.